is everyone on glp 1 GLP-1 The promise and peril of

Underlying Health Conditions Are Slowing Results Certain medical conditions can make weight loss more challenging

In many cases, definitive treatment of gallbladder disease allows patients to safely continue their GLP-1 medication if clinically indicated

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

"Randomized trial to evaluate the clinical benefits of serum alpha-glutathione S -transferase concentration monitoring after liver transplantation"

Becejac T et al